JPWO2022076987A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022076987A5 JPWO2022076987A5 JP2023520379A JP2023520379A JPWO2022076987A5 JP WO2022076987 A5 JPWO2022076987 A5 JP WO2022076987A5 JP 2023520379 A JP2023520379 A JP 2023520379A JP 2023520379 A JP2023520379 A JP 2023520379A JP WO2022076987 A5 JPWO2022076987 A5 JP WO2022076987A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- bispecific antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063088879P | 2020-10-07 | 2020-10-07 | |
| US63/088,879 | 2020-10-07 | ||
| PCT/US2021/071718 WO2022076987A1 (en) | 2020-10-07 | 2021-10-05 | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023545983A JP2023545983A (ja) | 2023-11-01 |
| JPWO2022076987A5 true JPWO2022076987A5 (https=) | 2024-10-10 |
| JP2023545983A5 JP2023545983A5 (https=) | 2024-10-10 |
Family
ID=78622127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520379A Pending JP2023545983A (ja) | 2020-10-07 | 2021-10-05 | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230365681A1 (https=) |
| EP (1) | EP4225793A1 (https=) |
| JP (1) | JP2023545983A (https=) |
| KR (1) | KR20230083300A (https=) |
| CN (1) | CN116685348A (https=) |
| WO (1) | WO2022076987A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137576A1 (en) * | 2023-12-22 | 2025-06-26 | Nutcracker Therapeutics, Inc. | Multiple specific antibodies targeting cd19, cd20, and/or cd47 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| AU2014227638A1 (en) * | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| HUE046661T2 (hu) * | 2014-08-15 | 2020-03-30 | Merck Patent Gmbh | SIRP-alfa immunglobulin fúziós proteinek |
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| CN109689684B (zh) | 2016-07-06 | 2022-09-23 | 细胞基因公司 | 具有低免疫原性的抗体及其用途 |
| BR112019020185A2 (pt) | 2017-03-27 | 2020-06-02 | Celgene Corporation | Métodos e composições para redução da imunogenicidade |
| WO2019109876A1 (zh) * | 2017-12-04 | 2019-06-13 | 北京韩美药品有限公司 | 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| AU2019218271B2 (en) * | 2018-02-12 | 2024-12-12 | Forty Seven, LLC | Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies |
-
2021
- 2021-10-05 JP JP2023520379A patent/JP2023545983A/ja active Pending
- 2021-10-05 WO PCT/US2021/071718 patent/WO2022076987A1/en not_active Ceased
- 2021-10-05 CN CN202180065527.0A patent/CN116685348A/zh active Pending
- 2021-10-05 KR KR1020237014459A patent/KR20230083300A/ko active Pending
- 2021-10-05 US US18/248,205 patent/US20230365681A1/en active Pending
- 2021-10-05 EP EP21807476.3A patent/EP4225793A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20220032568A (ko) | Flt3l-fc 융합 단백질 및 사용 방법 | |
| JP2022169709A (ja) | 関節リウマチの治療 | |
| KR20200118824A (ko) | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 | |
| CN1703243A (zh) | 针对erb－b1受体的药物组合物 | |
| CN108473578A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| EP1178826A1 (en) | Immunotherapy of b-cell malignancies using anti-cd22 antibodies | |
| CN1486191A (zh) | 使用受体酪氨酸激酶抑制剂和血管生成抑制剂的组合疗法 | |
| EP4210742A1 (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma | |
| WO2021041878A1 (en) | Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment | |
| JP2020507577A (ja) | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 | |
| IL301102A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma | |
| US20220313822A1 (en) | Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody | |
| JP2022544053A (ja) | 非枯渇性ｂ細胞阻害剤によって免疫原性を低下させるための方法および組成物 | |
| TW202131948A (zh) | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 | |
| WO2025122791A1 (en) | Use of anti-cd38 antibody in the treatment of new diagnosed multiple myeloma | |
| JPWO2022076987A5 (https=) | ||
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| CN121311504A (zh) | 用针对cd3和cd20的双特异性抗体治疗淋巴瘤的方法 | |
| CN118697865A (zh) | 治疗淋巴瘤的药物组合 | |
| KR20240135663A (ko) | 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 | |
| CN100408097C (zh) | 双特异性抗erb-b抗体及其在肿瘤治疗中的用途 | |
| JP7132256B2 (ja) | 関節リウマチの治療 | |
| CN112439060B (zh) | Pd-l1免疫疗法的新用途 | |
| US20230340136A1 (en) | Treatment of cll | |
| TW202541844A (zh) | Ｐｄ－１／ｉｌ－２ｒ雙特異性抗體融合蛋白及其用途和使用方法 |